Tower Research Capital LLC (Trc) Cyclacel Pharmaceuticals, Inc. Transaction History

Tower Research Capital LLC (Trc)

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	SELL	$0.28 - $0.75 $3 - $10	-14 Reduced 0.39%	3,591 $1,000
Q2 2023 Aug 14, 2023	SELL	$0.52 - $0.76 $18 - $27	-36 Reduced 0.99%	3,605 $2,000
Q1 2023 May 09, 2023	BUY	$0.56 - $1.15 $787 - $1,618	1,407 Added 62.98%	3,641 $2,000
Q4 2022 Feb 10, 2023	BUY	$0.54 - $21.75 $736 - $29,645	1,363 Added 156.49%	2,234 $1,000
Q3 2022 Nov 10, 2022	SELL	$1.23 - $21.9 $5,622 - $100,104	-4,571 Reduced 83.99%	871 $1,000
Q2 2022 Aug 15, 2022	BUY	$6.1 - $7.15 $12,712 - $14,900	2,084 Added 62.06%	5,442 $6,000
Q1 2022 May 12, 2022	BUY	$5.93 - $7.6 $18,726 - $24,000	3,158 Added 1579.0%	3,358 $10,000
Q4 2021 Feb 14, 2022	BUY	$6.04 - $8.03 $1,208 - $1,605	200 New	200 $1,000
Q3 2021 Nov 15, 2021	SELL	$8.02 - $11.0 $1,868 - $2,563	-233 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$7.59 - $10.48 $2,967 - $4,097	-391 Reduced 62.66%	233 $1,000
Q1 2021 May 17, 2021	BUY	$6.86 - $9.24 $3,724 - $5,017	543 Added 670.37%	624 $4,000
Q4 2020 Feb 16, 2021	BUY	$5.0 - $7.5 $405 - $607	81 New	81 $1,000

Ticker CYCC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 12,539,200
Market Cap $6.02M
Description
Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's development programs include fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combin...

Get notified when there are updates to the investment portfolio of Tower Research Capital LLC (Trc), based on Form 13F filings with the SEC.

Stay updated on Tower Research Capital LLC (Trc) with notifications on news.